#Halozyme hashtag - Bluesky

@newsen.bsky.social

3 days ago

Halozyme Partners with Vertex to Enhance Drug Delivery with Hypercon Technology Halozyme Therapeutics has announced a strategic partnership with Vertex Pharmaceuticals, focusing on the advanced Hypercon technology for drug delivery. This collaboration highlights the innovation in patient treatment methods.

Halozyme Partners with Vertex to Enhance Drug Delivery with Hypercon Technology #United_States #San_Diego #Halozyme #Vertex #Hypercon

0 0 0 0

Fazen Capital

@fazencapital.bsky.social

1 week ago

Halozyme CEO Sells $2.59m in Stock Halozyme CEO sold $2.59M in stock, reported Apr 2, 2026 (Investing.com). Verify via SEC Form 4; the sale is material but not definitive on fundamentals.

Halozyme CEO Sells $2.59m in Stock: Halozyme CEO sold $2.59M in stock, reported Apr 2, 2026 (Investing.com). Verify via SEC Form 4; the sale is material but not definitive on fundamentals. 👈 Read full analysis #Halozyme #StockMarket #CEO #Investing #FinanceNews

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

Halozyme Therapeutics Welcomes David Ramsay as Interim CFO for Future Growth Halozyme Therapeutics has appointed David Ramsay as the Interim CFO, bringing extensive financial leadership and experience in biotech to the role.

Halozyme Therapeutics Welcomes David Ramsay as Interim CFO for Future Growth #United_States #San_Diego #CFO #Halozyme #David_Ramsay

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

FDA Grants Approval for TECVAYLI® and DARZALEX FASPRO® Combination in Treating Relapsed Multiple Myeloma The U.S. FDA has approved the combination of TECVAYLI® and DARZALEX FASPRO® for treating adults with relapsed/refractory multiple myeloma, signaling a significant advancement in therapy options.

FDA Grants Approval for TECVAYLI® and DARZALEX FASPRO® Combination in Treating Relapsed Multiple Myeloma #United_States #San_Diego #Halozyme #DARZALEX #TECVAYLI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition Halozyme Therapeutics has raised its revenue estimates for 2025 and set ambitious financial guidance for 2026, driven by innovative acquisitions and strong royalty growth.

Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition #United_States #San_Diego #Halozyme #Therapeutics #ENHANZE

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Halozyme and Takeda Forge Partnership to Elevate Vedolizumab Treatment Accessibility Globally Halozyme and Takeda have signed an exclusive global deal to enhance the delivery of vedolizumab, leveraging Halozyme's innovative ENHANZE technology for better patient outcomes.

Halozyme and Takeda Forge Partnership to Elevate Vedolizumab Treatment Accessibility Globally #United_States #San_Diego #Halozyme #ENHANZE #Vedolizumab

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Halozyme and Skye Bioscience Forge Collaboration to Tackle Obesity with Nimacimab Halozyme and Skye Bioscience have entered a global partnership to develop Nimacimab with ENHANZE® technology, targeting obesity treatment. This collaboration aims to enhance drug delivery efficiency and evaluation of higher doses.

Halozyme and Skye Bioscience Forge Collaboration to Tackle Obesity with Nimacimab #USA #San_Diego #Halozyme #Skye_Bioscience #nimacimab

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

U.S. FDA Grants Approval for RYBREVANT FASPRO to Treat Advanced Lung Cancer The FDA has approved RYBREVANT FASPRO, a new treatment for advanced EGFR-mutated non-small cell lung cancer, enhancing administration efficiency.

U.S. FDA Grants Approval for RYBREVANT FASPRO to Treat Advanced Lung Cancer #United_States #San_Diego #Halozyme #ENHANZE #RYBREVANT

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Jim Lang Joins Halozyme Therapeutics as a New Board Member Halozyme Therapeutics has welcomed Jim Lang to its Board of Directors, bringing over 30 years of healthcare experience to the team.

Jim Lang Joins Halozyme Therapeutics as a New Board Member #United_States #San_Diego #biopharmaceuticals #Halozyme #Jim_Lang

0 0 0 0

@pharmalot.bsky.social

4 months ago

Merck suffers a setback over its new Keytruda formulation in Germany In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of

ICYMI: Merck suffers a setback over its new Keytruda formulation in Germany.. statnews.com/pharmalot/20... #pharma #cancer #Keytruda #Germany #patents #Merck #Halozyme

0 0 0 0

@pharmalot.bsky.social

4 months ago

Merck suffers a setback over its new Keytruda formulation in Germany In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of

Merck suffers a setback over its new Keytruda formulation in Germany.. statnews.com/pharmalot/20... #pharma #patents #Keytruda #Merck #Germany #Halozyme

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Halozyme Secures Preliminary Injunction Against Merck's Keytruda in Germany Amid Patent Dispute Halozyme has obtained a preliminary injunction from a German court against Merck regarding Keytruda SC, citing patent infringement concerns. This ruling halts the drug's distribution in Germany.

Halozyme Secures Preliminary Injunction Against Merck's Keytruda in Germany Amid Patent Dispute #Germany #Halozyme #Munich #KEYTRUDA #Merck

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Halozyme to Showcase Innovations at 8th Annual Evercore Healthcare Conference Halozyme Therapeutics, Inc. reveals Dr. Helen Torley will present at the Evercore Healthcare Conference, highlighting innovative drug delivery technologies.

Halozyme to Showcase Innovations at 8th Annual Evercore Healthcare Conference #United_States #San_Diego #Halozyme #ENHANZE #Hypercon

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Merus and Halozyme Join Forces to Enhance Subcutaneous Cancer Treatment Options Merus and Halozyme have announced a collaboration to develop a subcutaneous formulation of petosemtamab, aiming to improve cancer treatment delivery methods.

Merus and Halozyme Join Forces to Enhance Subcutaneous Cancer Treatment Options #United_States #San_Diego #Halozyme #Merus #Petosemtamab

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Halozyme Therapeutics Unveils Convertible Senior Notes Offering Worth $650 Million Due in 2031 and 2032 Halozyme Therapeutics, Inc. has announced a proposed offering of $650 million in convertible senior notes due in 2031 and 2032, aiming to strengthen their financial position in the market.

Halozyme Therapeutics Unveils Convertible Senior Notes Offering Worth $650 Million Due in 2031 and 2032 #United_States #San_Diego #Halozyme #Convertible_Notes #Securities_Offering

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Halozyme Reports Impressive Financial Growth and Raises Guidance for 2025 Halozyme Therapeutics shares quarterly results showing significant revenue growth, raising 2025 guidance with remarkable achievements in drug delivery technology.

Halozyme Reports Impressive Financial Growth and Raises Guidance for 2025 #United_States #San_Diego #Halozyme #ENHANZE #Elektrofi

0 0 0 0

@emergingtechnews.bsky.social

6 months ago

Acquisitions: #31C > #Xynthor; #Carta > #Accelex; #Credo > #Hyperlume; #Databrick > #Mooncake; #EnteroTherapeutics > #GRIDAI; #Halozyme > #Elektrofi; #Harness > #QwietAI; #HoneyBook > #Fine.dev; #Insight > #Inspire11; #Karbon > #Aider; #Lightcast > #Simply

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Halozyme Therapeutics Set to Engage Investors at Key Upcoming Conferences Halozyme Therapeutics will actively engage with investors at notable upcoming conferences, showcasing their innovations and strategic goals in the biopharmaceutical space.

Halozyme Therapeutics Set to Engage Investors at Key Upcoming Conferences #United_States #San_Diego #Halozyme #ENHANZE #Dr._Helen_Torley

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Halozyme Therapeutics Reports Significant Financial Growth for Q2 2025 with Raised Guidance Halozyme Therapeutics shows remarkable revenue growth in Q2 2025, prompting an upward revision of its financial guidance for the year, reflecting confidence and market demand.

Halozyme Therapeutics Reports Significant Financial Growth for Q2 2025 with Raised Guidance #USA #San_Diego #Halozyme #ENHANZE #Drug_Delivery

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

European Commission Grants Approval for DARZALEX Faspro® to Treat High-Risk Smouldering Multiple Myeloma The recent approval by the European Commission for DARZALEX Faspro® signifies a major advancement in treating smouldering multiple myeloma at risk patients, enhancing early intervention opportunities.

European Commission Grants Approval for DARZALEX Faspro® to Treat High-Risk Smouldering Multiple Myeloma #United_States #San_Diego #Halozyme #DARZALEX_FASPRO #Janssen-Cilag

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Halozyme Therapeutics to Engage in Key Investor Conferences in June 2025 Halozyme Therapeutics announces participation in two major investor conferences, aiming to connect and engage with potential investors on upcoming advancements in healthcare.

Halozyme Therapeutics to Engage in Key Investor Conferences in June 2025 #United_States #San_Diego #Halozyme #ENHANZE #Dr._Helen_Torley

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

Halozyme Therapeutics Celebrates Positive CHMP Opinion for argenx's VYVGART® Injection in CIDP Treatment Halozyme Therapeutics announces a favorable opinion from the CHMP for VYVGART® in treating CIDP. This groundbreaking therapy is nearing approval.

Halozyme Therapeutics Celebrates Positive CHMP Opinion for argenx's VYVGART® Injection in CIDP Treatment #United_States #San_Diego #Halozyme #CIDP #VYVGART®

0 0 0 0

@pharmalot.bsky.social

11 months ago

Pharmalittle: We're reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney, and more In today's Pharmalittle roundup, we're reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney, and more.

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney & more news.. statnews.com/pharmalot/20... #pharma #Trump #tariffs #patents #Keytruda #FDA #DOGE #layoffs #NEJM #bias #Merck #Roche #Halozyme

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

Halozyme Takes Legal Action Against Merck for Patent Violation of Keytruda's Subcutaneous Delivery Method Halozyme Therapeutics files a lawsuit against Merck for allegedly infringing on its patents related to subcutaneous administration technology for Keytruda, seeking damages and injunctive relief.

Halozyme Takes Legal Action Against Merck for Patent Violation of Keytruda's Subcutaneous Delivery Method #United_States #San_Diego #Halozyme #KEYTRUDA #Merck

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Halozyme Secures FDA Approval for VYVGART® Hytrulo Prefilled Syringe Targeted at Myasthenia Gravis Patients Halozyme has announced that argenx received FDA approval for VYVGART® Hytrulo prefilled syringe, enhancing treatment options for myasthenia gravis and CIDP patients.

Halozyme Secures FDA Approval for VYVGART® Hytrulo Prefilled Syringe Targeted at Myasthenia Gravis Patients #USA #San_Diego #FDA_Approval #Halozyme #VYVGART

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

European Commission Greenlights Subcutaneous DARZALEX® Treatment for Newly Diagnosed Multiple Myeloma Patients The European Commission has approved a new treatment regimen involving subcutaneous DARZALEX®, offering hope to patients with newly diagnosed multiple myeloma.

European Commission Greenlights Subcutaneous DARZALEX® Treatment for Newly Diagnosed Multiple Myeloma Patients #None #Halozyme #Multiple_Myeloma #DARZALEX

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago